Carey K. Anders, MD

Assistant Professor

University of North Carolina at Chapel Hill

Dr. Anders is a clinician-scientist and an Assistant Professor of Medicine at the University of North Carolina (UNC) School of Medicine, a member of both the UNC Lineberger Comprehensive Cancer Center and the UNC Breast Center. Her research focuses on the biology of breast cancer. During her fellowship she did research examining age-specific genomic differences in human breast carcinoma. She has addressed brain metastases arising from breast cancer. Dr. Anders has served as the Principal Investigator of a Cancer and Leukemia Group B (CALGB) Young Investigator Award examining the activation status of important oncogenic signaling pathways in human breast carcinoma brain metastases. She conceived, designed and serve as the PI of two, multicenter, phase II studies in the setting of breast cancer brain metastases – one testing iniparib in triple negative breast cancer; the second mTOR inhibition in Her2-positive breast cancer. In parallel and supported by the UNC Chapel Hill Hematology Oncology K12 and NIH/NCI K23, she has developed several intracranial breast cancer tumor models to test novel therapies, including small molecule and nanoparticle chemotherapeutics.

William F. Anderson, MD, MPH

Senior Investigator

National Cancer Institute

Dr. Anderson received his medical, clinical, and epidemiological training at Tulane School of Medicine University in New Orleans Louisiana. He is board certified in Internal Medicine, Hematology, and Medical Oncology. After nearly 20 years as a community-based Medical Oncologist in Monroe Louisiana, Dr. Anderson moved to the National Cancer Institute to develop a research program in Cancer Surveillance Research. He supplements standard descriptive epidemiology with biostatistical models to assess cancer trends, heterogeneity, racial and geographic disparities in population-based cancer registries.

Carlos L. Arteaga, MD

Professor of Medicine & Cancer Biology

Vanderbilt-Ingram Cancer Center

Carlos L. Arteaga obtained his M.D. degree with honors in 1980 at the University of Guayaquil in Guayaquil, Ecuador. He trained in Internal Medicine and Medical Oncology at Emory University (Atlanta, GA) and the University of Texas Health Sciences Center in San Antonio, TX, respectively. He joined the Vanderbilt faculty in 1989 where he now holds the Donna S. Hall Chair in Breast Cancer Research and .serves as Professor of Medicine and Cancer Biology in the Division of Hematology-Oncology in the Department of Medicine. Dr. Arteaga is Associate Director for Clinical Research at the NCI-designated Vanderbilt-Ingram Comprehensive Cancer Center (VICC) and directs the Breast Cancer Program of the VICC. He has over 250 publications in the areas of signaling by growth factor receptors and oncogenes in breast tumor cells as well as the development of molecular therapeutics and biomarkers of drug action in breast cancer. Dr. Arteaga directs the NCl-funded Vanderbilt Breast Cancer SPORE where he leads a number of investigator-initiated clinical trials. He is funded by NCI, ACS, the DOD Breast Cancer Research Program, Stand Up 2 Cancer/AACR, and the Komen and Breast Cancer Research Foundations. He is certified by the American Board of lnternal Medicine in Internal Medicine and in Medical Oncology. In 1998 he was elected into the American Society of Clinical Investigation (ASCI) and in 2005 into the Association of American Physicians (AAP). He serves (or has served) as member of the NCI Parent Committee for Review of Cancer Centers (Subcommittee A; 2004-2008), the Board of Scientific Advisors of the National Cancer Institute (1999-2004), the Breast Cancer Core Committee of the Eastern Cooperative Oncology Group (ECOG), and the Board of Directors of the American Association for Cancer Research (AACR; 2004-2007). He co-chaired the Developmental Therapeutics Committee of ECOG and chaired the Special Conferences Committee of the AACR (2002-2008). Dr. Arteaga is the recipient of the 2003 AACR Richard & Hinda Rosenthal Award and more recently received the 2007-2012 ACS Clinical Research Professorship Award, the 2009 Gianni Bonadonna Award from the American Society of Clinical Oncology (ASCO), and the 2011 Brinker Award for Scientific Distinction from the Susan G. Komen for the Cure Breast Cancer Foundation. He has chaired the AACR Special Conference Advances in. Breast Cancer Research in 2003, 2005, 2007, and 2009. He is Deputy Editor of Clinical Cancer Research and Associate Editor or member of the Editorial Board of Cancer Cell, the Journal of Mammary Gland Biology & Neoplasia, Breast Cancer Research, Molecular Cancer Therapeutics, Journal of Clinical Oncology (past), Clinical Proteomics, and Cancer Biology & Therapy.

Donald A. Berry, PhD

Professor

Department of Biostatistics

UT MD Anderson Cancer Center

Donald A. Berry is a professor in the Department of Biostatistics of the University of Texas M.D. Anderson Cancer Center. Dr. Berry received his Ph.D. in statistics from Yale University, and previously served on the faculty at the University of Minnesota and at Duke University. He has held endowed faculty positions at Duke University and M.D. Anderson. Dr. Berry is the author of several books on biostatistics and over 300 published articles and principal investigator for numerous research grants from the NIH and NSF. He is a Fellow of the American Statistical Association and of the Institute of Mathematical Statistics.

Malcolm K. Brenner, MD, PhD

Center Director/Professor

Center for Cell and Gene Therapy

Baylor College of Medicine

Dr. Malcolm Brenner, M.D., PhD., is Director of the Center for Cell and Gene Therapy at Baylor College of Medicine (BCM), Texas Children'S Hospital and The Methodist Hospital. He serves as a professor, in the Departments of Pediatrics and of Medicine at BCM. Brenner received his medical degree and subsequent PhD. from Cambridge University, England. Brenner's clinical research interests span many aspects of stem cell transplantation, using genetic manipulation of cultured cells to obtain therapeutic effects. Efforts in Brenner's laboratory to analyze the cell of origin when relapse occurs in patients with acute myelogenous leukemia led Brenner's team to be the first to label autologous bone marrow cells genetically after purging, prior to being reintroduced to the patient. He is studying the effects of gene transfer into autologous neuroblastoma cells and the use of gene-modified EBV-specific cytotoxic T Iymphocyctes for prevention and treatment of Iymphoproliferative disorders, Hodgkin's disease, lung cancer and neuroblastoma. His group recently pioneered the first clinical use of a new safety switch for cellular therapy. Brenner is Editor in Chief of "Molecular Therapy" and a former President of the American Society for Gene and Cell Therapy (ASGCT) and the International Society for Cell Therapy. He has won many awards for his work and in 2011 these included the ASGCT Outstanding Achievement Award and the American Society of Hematology Mentor Award.

Jane Elizabeth Brock, MBBS, PhD

Associate Pathologist

Brigham and Women's Hospital

Jane E. Brock, is an Assistant Professor of Pathology at Harvard Medical School and Associate Pathologist at Brigham and Women's Hospital (BWH) and Dana Farber Cancer Institute (DFCI), Boston, MA.  She covers both general surgical pathology and a high volume subspecialty breast pathology service including institutional consults for DFCI.  She evaluates pathology for breast cancer clinical trials running at the Dana Farber Breast Cancer Center and has focused her academic research on pathologic prognostic factors in breast cancer including ER and HER2/neu status evaluation and prognostic factors in microinvasive breast carcinomas.  She is also the Medical Director of the BWH Surgical Pathology Grossing Room and supervises the training of residents and fellows in surgical pathology at BWH.

Powel H. Brown, MD, PhD

Professor and Chairman

UT MD Anderson Cancer Center

Dr. Brown is Professor and Chairman of The University of Texas MD Anderson Cancer Center's Department of Clinical Cancer Prevention . He also holds a joint appointment in the Department of Breast Medical Oncology . He's conducted clinical, translation , and laboratory-based breast cancer research to identify ways to prevent breast cancer , especially the most aggressive from of this disease, "triple-negative breast cancer". In his laboratory, they study the process of transformation. They also attempt to identify individuals with premalignant lesions who can then be treated to prevent progression to invasive breast cancer.

He has published extensively in leading high-impact, peer-reviewed journals including Journal of the National Cancer Institute, Journal of Biological Chemistry, Cancer Research, Oncogene, Clinical Cancer Research, and Cancer Prevention Research. Since 2008, he has served as chairman of the Cancer Prevention Committee for the Southwest Oncology Group.

For more than 20 years, he has provided cancer treatment and cancer preventive care to patients. In his clinical research program, they are testing novel drugs and strategies to prevent cancer. In his clinical practice, he manages women at high risk of breast cancer (many of which have premalignant breast lesions).

Harold J. Burstein, MD, PhD

Associate Professor of Medicine

Dana-Farber Cancer Institute

Harold J. Burstein, MD, PhD is an Associate Professor of Medicine at Harvard Medical School, and a medical oncologist at Dana-Farber Cancer Institute and Brigham & Women's Hospital.  He is a clinical and clinical investigator specializing in breast cancer.

Dr. Burstein attended Harvard College, and earned his MD at Harvard Medical School where he also earned a PhD in immunology.  In addition, he holds a master's degree in history of science from Harvard.  He trained in internal medicine at Massachusetts General Hospital, and was a fellow in medical oncology at Dana-Farber before joining the staff.

Dr. Burstein's clinical practice is devoted entirely to breast cancer patients.  His clinical research interests include novel treatments for early - and advanced-stage breast cancer, and studies of quality of life and health behavior among women with breast cancer.  Dr. Burstein has written widely on breast cancer in both traditional medical journals and on the web.  Representative publications of Dr. Burstein's can be found in the New England Journal of Medicine, the Journal of Clinical Oncology, and other leading medical journals.  He serves on international committees focusing on cancer treatments including the NCCN Breast Cancer Panel, The St. Gallen Breast Cancer Panel, and the Alliance Breast Cancer Committee.  He is chair of the ASCO guideline on endocrine therapy for breast cancer.  Dr. Burstein is editor-in-chief of the Journal of the National Comprehensive Cancer Network.  Dr. Burstein teaches students, house staff, and fellows at Harvard Medical School, Dana-Farber, Brigham & Women's Hospital, and affiliated training hospitals.

Lisa A. Carey, MD

Distinguished Professor

University of North Carolina

Lisa A. Carey, MD, is the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research in the UNC Department of Medicine, Division of Hematology-Oncology. In September of 2012, Dr. Carey became the Division Chief of Hematology and Oncology, as well as the Physician-in-Chief of the North Carolina Cancer Hospital. She graduated from Wellesley College in 1984 with a B.A. in Biology and Art History. She received her M.D. from the Johns Hopkins University School of Medicine in 1990. She remained at Johns Hopkins for her residen1oy in Internal Medicine followed by a fellowship in Medical Oncology and an advanced degree in Clinical Investigations. Dr. Carey joined the UNC faculty and Lineberger Comprehensive Cancer Center in 1998. At UNC-Lineberger, she is the Medical Director of the Breast Center, Section Chief of Breast Medical Oncology, co-Leader of the Breast Cancer Research Program, and chairs the Oncology Protocol Review Committee. She became the Cancer Center's Associate Director for Clinical Research in 2010.

Dr. Carey has a longstanding research interest in the clinical application of laboratory findings in breast cancer; with a particular interest in the clinical implications of different molecular subtypes of breast cancer.  She designs and leads clinical trials of novel drugs and approaches, and is a close collaborator with several laboratory investigators and epidemiologists.  Dr. Carey has served on the American Society of Clinical Oncology (ASCO) Scientific Program and Education Committees and as faculty for ASCO and AACR-CTRC San Antonio annual meetings for many years.  She was named to the Cancer and Leukemia Group B (CALGB) Breast Core Committee in 2003.  She was awarded a Doris Duke Clinician Scientist Award in 1999, a Career Development Award from the NCI in 2000, and was inducted into the Johns Hopkins Society of Scholars in 2008.  In 2011 Dr. Carey was awarded the NCI Director's Service Award.

Lewis A. Chodosh, MD, PhD

Professor of Cancer Biology

University of Pennsylvania

Bio not available

David Cortez, PhD

Ingram Professor of Cancer Research

Professor of Biochemistry

Vanderbilt University School of Medicine

Dr. Cortez graduated Summa Cum Laude from the University of Illinois at Champaign-Urbana with Highest Honors in Biology and Biochemistry. He received his Ph.D. degree in 1997 in Molecular Cancer Biology from Duke University. After post-doctoral training as a Jane Coffin Childs Fellow with Stephen Elledge at the Baylor College of Medicine he joined the Vanderbilt faculty in 2002. He was promoted to Associate Professor in 2007 and Professor of Biochemistry and Ingram Professor of Cancer Research in 2009. He is Director of Graduate Studies in the Department of Biochemistry, and a member of the Editorial Boards of the journals Cell Reports, Molecular and Cellular Biology and Journal of Biochemistry. He became co-leader of the Genome Maintenance Program in the Vanderbilt-Ingram Cancer Center upon its inception in 2007.

Dr. Cortez’s research focuses on the mechanisms that regulate cellular responses to DNA damage and DNA replication stress. His laboratory has made significant discoveries into how DNA damage response signaling pathways are activated and control cell cycle checkpoints. Furthermore, his research has identified new proteins that function to maintain genome integrity during DNA replication and DNA repair. His research has been published in journals including Science, MCB, JBC, PNAS, Molecular Cell, and Genes and Development. He has received several awards recognizing his scientific achievements including the Howard Temin Award from the National Cancer Institute, the Wilson S. Stone Memorial Award, and a Pew Scholar Award from the Pew Charitable Trusts.

Massimo Cristofanilli, MD

Medical Oncologist

Thomas Jefferson University

During Dr. Cristofanilli training he participated in the evaluation and organization of educational event as Chief Medical Resident at the Cabrini Medical Center in NYC.  He completed his fellowship in Medical Oncology at the University of Texas, M D Anderson Cancer Center.  Subsequently, he joined the faculty in the Department of Breast Medical Oncology.  He participated in the training and educational of fellows and received recognition as "Outstanding Educator Award" in 2003 and Distinguished Alumnus Award in 2008.  As a member of the ASCO review Committee he participated in abstract review process and selection (2005-2007).  He has also been involved in abstract review for ASCO and grant review for SGK foundation, DOD and ACS.  His pioneer work on circulating tumor cells (CTCs) stimulated research on the detection, prognostic value and molecular characterization of microscopic disease in advanced solid tumors. He was founder and Executive Director of the Morgan Welch Inflammatory Breast Cancer Research and Clinic (2006-2009).  He organized the International Inflammatory Breast Cancer Conference (2008, 2012) providing educational opportunity for health care providers and advocates in relation to this aggressive disease.

Richard L. Crownover, MD, PhD

Residency Program Director

UT Health Science Center San Antonio

Bio not available

Jack Cuzick, PhD

Head of Centre

Queen Mary University of London

Jack Cuzick is head of the Centre for Cancer Prevention in London. He is also John Snow Professor of Epidemiology at Wolfson Institute of Preventive Medicine at Queen Mary, University of London. He holds a PhD in Mathematics and has previously worked at Oxford University and Columbia University, New York. His current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening. He is currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. He has worked extensively in breast cancer and was the first to f report the effect of tamoxifen on contralateral tumours as an indicator of its potential chemopreventive role and also has demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness. He is also involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behaviour of early prostate cancer. He is the statistician for several major breast cancer trials and maintains an active interest in developing new statistical methodology, especially in the area of adjustments for non-compliance and cross-over, and multi-arm clinical trials. He is currently the President of the International Society of Cancer Prevention and is a Fellow of the Academy of Medical Sciences, the Royal Statistical Society, the Institute of Mathematical Statistics and an Honorary Fellow of the Royal College of Physicians. In 2007, he was chosen by Thompson Scientific as one of the twelve hottest researchers in all of science. He was awarded the the AACR Cancer Prevention Prize in 2012. He is the author of more than 480 peer-reviewed papers and has published in all the major medical journals.

John E. Dick, PhD

Senior Scientist

Ontario Cancer Institute

Bio not available

Lesley Fallowfield, BSc, DPhil, FMed Sci

Director Psychosocial Oncology

University of Sussex

Leslie Fallowfield is Professor of Psycho-oncology at Brighton & Sussex Medical School, Universit of Sussex where she is Director of the Susex Health Outcomes Research & Education in Cancer (SHORE-C) group. Professor Fallowfield originally trained as a nurse at Guy's Hospital London but then completed a BSc in Experimental Psychology. Research for her doctorate in psychophysics was conducted at the Universities of Sussex and Cambridge. She was a senior lecturer in health psychology at the Royal London Medical College where she gained a career development fellowship and a major programme grant from the Cancer Research Campaign. In 1991she became full-time Director of the Psyschosocial Oncology Group and was awarded the first European chair of Psycho-oncology from University College London in 1997. Her research interests are wide and include the velopment of psychometric tools and measurement of quality of life in many major international clinical trials of cancer therpay especially breast cancer. She and her team have also developed and evaluated evidence based communication skills training programmes for health care professionals in cancer. She holds many research grants, has written > 350 papers, many books chapters and 3 text books. She lectures and runs training workshops throughout the world in psychosocial oncology, quality of life assessment and communication skills. Her expertise in these fields has resulted in many prestigious eponymous lectures and awards. In 2008 she was made a Fellow of the UK Academy of Medical Sciences. In 2010 she was shortlisted for the British Medical Journal's Lifetime Achievement Award and won the Pfizer/British Oncology Associations' Excellence in Oncology, Lifetime Achievement Award.

Barbara Fowble, MD, FACR, FASTRO

Health Sciences Clinical Professor

University of California San Francisco

Before joining the faculty at UCSF, Dr. Barbara Fowble was the Clinical Director of the Radiation Oncology Department, Associate Director of the Breast Evaluation Center and a Senior Member of the division of medical science at Fox Chase cancer Center (an NCI designated comprehensive cancer center) in Philadelphia, Pennsylvania. She is internationally recognized for her expertise in radiation and breast cancer. Her research studies have defined the roles of breast conservation therapy as an alternative to mastectomy and radiation after mastectomy. She was the founder and the inspiration for the Fox Chase Cancer Center Complementary Medicine Program, “Complete Care”. Dr. Fowble has been selected as one to the top physicians in the United States by such publications as American Health magazine, Best Doctors in America, Good Housekeeping, Town and Country and Philadelphia Magazine. She was featured in Time-life’s medical video on breast cancer. She is the author of numerous scientific publications and was the primary editor of a textbook on breast cancer treatment. She has served on the editorial boards of the Journal of Clinical Oncology and the International Journal of Radiation Oncology, Biology, and Physics. She was a guest editor for Breast Diseases: A Yearbook Quarterly and associate editor for the Breast Journal. Her current interests focus on complications of post-mastectomy radiation in patients undergoing reconstruction, defining the role of post-mastectomy radiation in women receiving neoadjuvant chemotherapy and the role of breast conserving surgery and radiation in young women with breast cancer. She is a fellow of the American College of Radiology and the American Society of Therapeutic Radiology and Oncology.

Suzanne A. W. Fuqua, PhD

Professor

Baylor College of Medicine

Dr. Suzanne AW Fuqua's laboratory is examining the role of estrogen receptors (ER) a and b, and the progesterone receptor (PR) A and B isoforms in hormone response, and breast cancer metastasis using clinical material, breast cancer cell lines, and transgenic mouse model systems. Furthermore, she was the first to discover a somatic ER mutant and alternatively spliced forms of ERa, which are thought to be important in the response of patients to treatment, and the development of breast cancer metastases. She has completed large retrospective clinical studies demonstrating 1) that low levels ERb are associated with resistance to tamoxifen antiestrogen therapy in patients, 2) that PR-positive patients with high levels of the A isoform are also resistant to hormonal therapies, and 3) that a ER mutation at lysine residue 303 enhances estrogen hypersensitivity and alters treatment responsiveness. These studies are the first to identify these receptors as predictive markers in large, multivariate analyses.

Dr. Fuqua is also elucidating the complex molecular alterations and mechanisms resulting in acquired resistance by utilizing genomics-based methodologies, such as microarray expression analyses. She is Director of the Breast Center microarray core. The main goal of her laboratory remains to understand the central role of the ER and its associated secondary signaling cascades in the progression of breast cancer patients, and the identification of novel markers of disease outcome. She has discovered several novel mechanisms of tamoxifen resistance using metastatic patient tumors. These include the involvement of the androgen receptor (AR) in resistance to antiestrogen, the role of Rho GDI in resistance and metastatic behavior of ER-positive cells, the role of Dicer --the stem cell and microRNA regulator, in tumor progression, and the impact of metastasis associated protein (MTA) 2 on the metastasis of ER-negative cancer.

Elizabeth Garrett-Mayer, PhD

Professor and Director of Biostatistics

Medical University of South Carolina

Elizabeth Garrett-Mayer, PhD is Director and Associate Professor of Biostatistics at the NCI-Designated Hollings Cancer Center (HCC) at the Medical University of South Carolina. She is a graduate of Bowdoin College and Johns Hopkins Bloomberg School of Public Health. Dr. Garrett-Mayer served for seven years as a member and for one year as the chair of the Scientific Clinical Review Committee for the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. She has been a member of the Protocol Review Committee for more than four years and Co-Chair of the Data Safety and Monitoring Committee at HCC. She serves as Co-Chair of Biostatistics for the Translational Breast Cancer Research Consortium. She has co-authored more than 170 peer-reviewed papers, mostly in cancer research. Her research interests are in adaptive designs in phase I studies and phase II studies. She recently co-edited a book “Principles of Anti-Cancer Drug Development". She has served on the educational committees for AACR's and ASCO's annual meetings. This year Dr. Garrett-Mayer is serving on the faculty at the Vail Workshop for her 10th year and she served as Course Director for three years (2008-2010). She is a member of the NIH Clinical Oncology study section and recently served a three year term as a reviewer for ASCO's Conquer Cancer Foundation grants. In addition to teaching and mentoring graduate students pursuing degrees in biostatistics and epidemiology, Dr. Garrett-Mayer mentors junior faculty pursuing research in clinical, translational and basic science oncology.

Michael Gnant, MD, FACS

Professor of Surgery

Medical University of Vienna

Dr. Michael Unant is Full Professor of Surgery at the Medical University of Vienna, Austria, where he also serves as President of the Austrian Breast and Colorectal Cancer Study Group. His medical career began in 1988 when he graduated in medicine in Vienna. He then specialized in surgery (1994) and surgical oncology. In 1997 and 1998 he worked as a Visiting Scientist at the National Cancer Institute, NIH, Bethesda, USA, and in 2004 he became Full Professor at the Medical University of Vienna. Since 2010, he acts as Co-ordinator of the Comprehensive Cancer Center Vienna. In 2005 he was elected President of the Austrian Breast & Colorectal Cancer Study Group (ABCSG). In 2009, he was appointed as future Chairman of the Department of Surgery at the Medical University of Vienna.

Professor Gnant has published more than 350 original papers in peer-reviewed Journals, more than 1 .400 abstracts, and he has given more than 1000 lectures at national and international meetings, including Plenary and Highlight Lectures at ASCO, EBCC, and SABCS. In addition, he has been the recipient of multiple national and international awards including the Grand Central European Award for Clinical Cancer Research, Best Paper l Best Poster Awards, the Award for Interdisciplinary Research in Oncology, and the prestigious Claudia-von-Schilling award by Hanover Universe. He also serves an the famous St. Gallen Consensus Panel for Early Breast Cancer since 2007 (moving to Vienna in 2015), and was elected to the European Academy of Science and Arts in 2009. Among other honors, he is a Fellow of the American College of Surgeons.

Dr. Gnant's research interests include several fields of surgical oncology, in particular breast and pancreatic cancer, immunotherapy using antibodies, vaccination with dendritic cells, endocrine intervention, dormant tumor cells, the use of bone targeted treatments in order to silence tumor micrometastases, and pathway directed therapies such as mTOR inhibition. He has been the Principal Investigator of more than 30 clinical trials.

He is involved in many scientific societies, including the American Society of Clinical Oncology, American Association of Cancer Research, ACS, Breast International Group, EUSOMA, and the European Society of Surgical Oncology. Among other activities, he currently serves as an Executive Board member (treasurer since 2005) of B .I .G., independent Reviewer and IDMC member for the European Organization for Research and Treatment of Cancer, the UICC, and other international bodies, and Scientific Reviewer and Process Evaluator for the European Union . He has been a member of the ethical committee of the Vienna Medical University since 2000 and assessor since 2001.

In addition to these responsibilities, he serves as Editor-in-Chief as well as an editorial boards for several Journals and serves as reviewer for many peer-reviewed journals, including The Lancet, The New England Journal of Medicine, Clinical Cancer Research, International Journal of Cancer, The Lancet Oncology, Journal of Clinical Oncology, Breast Cancer Research and Treatment, Breast Care, and Annals of Oncology.

Adrian L. Harris, BSc DPhil

Professor of Medical Oncology

Oxford University

Adrian L Harris is the Cancer Research UK Professor of Medical Oncology at the University of Oxford and directs the Cancer Research UK Molecular Oncology Labroatories at the Weatherall Institute of Molecular Medicine. He is Director of the Cancer Research UK Medical Oncology Unit at the Churchill Hospital, is a Consultant Medical Oncologist and a Professorial Fellow of St Hugh’s College Oxford. He is Head of the CRUK Oxford Cancer Centre and the Oxford Experimental Cancer Medicine Centre Centre. He is Editor-in-Chief of the British Journal of Cancer.

He trained in Medicine and Biochemistry at Liverpool University, did a DPhil at Oxford University then trained at the Royal Marsden Hospital in Medical Oncology. He was appointed Professor of Clinical Oncology at Newcastle-upon-Tyne in 1982. Since 1988 he has been the Professor of Medical Oncology at Oxford University, his major laboratory interests involve the role of hypoxia in breast tumour biology and tumour angiogenesis, the metabolic response to hypoxia, microRNAs induced by hypoxia and hypoxia-induced cell death. He has conducted many studies in new drug development and molecular pathology studies to translate laboratory findings to clinical relevance and development of new agents.

In the clinical department over 20 Phase I and II trials are run and current trials include new drugs blocking angiogenesis, HDAC inhibitors and blockers of signal transduction. Specific emphasis is on classification of tumours by functional imaging, molecular profiles, and pharmacodynamic endpoints. Specific clinical research interests for the unit include inhibition of angiogenesis, blockade of signal transduction and modulation of metabolism.

Nola Hylton, PhD

Professor of Residence, Radiology

University of California, San Francisco

Nola Hylton, Ph.D. is Professor of Radiology and Biomedical Imaging and Director of the Breast MRI Research Program at University of California, San Francisco . Her research focuses on the development and clinical optimization of MRI for breast cancer detection , diagnosis and staging . Dr. Hylton has been a key participant in several significant national and international efforts to define the role of MRI in breast cancer management, including serving as co-leader of the OHHS Office on Women 's Health International Working Group on Breast MRI, institutional Pl for the first large multi-center clinical trial evall.1ating breast MRI for breast cancer diagnosis and staging (NCI International Breast MRI Consortium) , and co-chair of the American College of Radiology (ACR) Breast MRI Lexicon Committee , which developed the ACR  Breast Imaging Reporting and Data System (BlRADS) for breast MRI, first published in 2003 .  Dr. Hylton serves as national Pl for the multi-center American College of Radiology Imaging Network (ACRIN) trials 6657 and 6698 , evaluating dynamic contrast-enhanced  (OCE) and diffusion-weighted (OW) MRI respectively , for assessing breast cancer response to neoadjuvant treatment.   Or. Hylton also leads two efforts to improve the integration of quantitative  imaging (QI) in breast cancer clinical trials through the development of software tools that can be used in real-time to measure breast tumor response (NCI Academic-Industrial  Partnership grant CA 132870) and the development of standards and quality control processes for QI in breast cancer clinical trials (NCI Quantitative Imaging Network (QIN) grant CA151235) .  She is a member of the ACRIN Breast Committee, CALGB Imaging Committee , ACR Accred itation Committee for Breast MRI, Susan G. Komen Scholars and has served on and chaired numerous grant review panels in the areas of medical imaging and breast cancer , including as chair of the NIH MEDI Study Section from 2004-2006 , member of the DOD Breast Cancer Research Program Integration Panel from 2008-2011 and as a member of the NIH NIBIB Council since 2010 .

Ismail Jatoi, MD, PhD, FACS

Professor and Division Chief Surgical Oncology

UT Health Science Center San Antonio

San Antonio, TX

Dr. Ismail Jatoi is Professor and Chief of the Division of Surgical Oncology at the University of Texas Health Sciences Center in San Antonio, Texas.   He is the holder of the Dale H. Dorn Endowed Chair in Surgery.  Dr. Jatoi obtained his undergraduate bachelor’s degree from Washington University in St. Louis and his MD and PhD degrees from St. Louis University.  He is a diplomate of the American Board of Surgery and a fellow of the American College of Surgeons.  He completed fellowship training in surgical oncology at the Royal Marsden Hospital in London, England.  Dr. Jatoi served in the U.S. military for many years, and was a Professor of Surgery at the Uniformed Services University in Bethesda, Maryland.  He retired from the U.S. Army with the rank of Colonel.  Dr. Jatoi has had a longstanding interest in breast cancer local therapy and adjuvant systemic therapy, the management of women at increased risk for breast cancer, and breast cancer screening.  He also has an interest in the design and analysis of cancer clinical trials.  Dr. Jatoi has previously served on the Breast Cancer Executive Committee of the Southwest Oncology Group (SWOG).  He is the Principal Investigator of the National Surgical Adjuvant Breast and Bowel Project (NSABP) at the University of Texas Health Science Center in San Antonio, and serves on the national NSABP Working Group.

Stephen R D Johnston, MA, FRCP, PhD

Consultant Medical Oncologist

The Royal Marsden NHS Foundation Trust

Bio not available

Rong Li, PhD

Professor

UT Health Science Center San Antonio

Bio not available

David C. Lyden, MD, PhD

Associate Professor

Weill Cornell Medical College

Dr. Lyden was educated at Brown University (MD), University of Vermont (PhD), Duke University (Residency) and Memorial Sloan-Kettering Cancer Center (Fellowship). Presently, he is the Stavros S. Niarchos Chair and Associate Professor of Pediatrics and Cell and Developmental Biology at Weill Cornell Medical Center and a Pediatric Neuro-Oncologist at Memorial Sloan-Kettering Cancer Center, and faculty member of the MD/PhD program at the Tri-Institute (Rockefeller University/Weill Cornell Medical College/Memorial Sloan Kettering Cancer Center). Recently, he was elected Investigator of the Champalimaud Metastasis Center, first for its kind for research, prevention and treatment of metastatic disease in Lisbon, Portugal (official opening October 5, 2010).

He has made several fundamental discoveries which involve the role of bone marrow-derived stem and progenitor cells in tumor vasculogenesis and in metastasis. His laboratory showed the first evidence of genetic regulation in vasculogenesis with the discovery of one family of genes called Id1-4 in early blood vessel development in embryogenesis and in tumorigenesis (Nature 1999, 401:670-677).  He and his colleagues were the first to identify two bone marrow-derived cells, endothelial progenitor cells (EPCs) and hematopoietic progenitor cells (HPCs) that both participate in the formation of new blood vessels in the primary tumor that occurred by vasculogenesis as opposed to angiogenesis or branching from pre-established blood vessels (Nature Medicine 2001, 9:702-712). This work has initiated other investigations of various populations of bone marrow-derived cells in tumor biology.

In recent years, his team has shown evidence that growth factors secreted by the primary tumor prime certain tissues for tumor cell engraftment (Nature 2005, 438:820-827). In response to these soluble factors, tumor associated cells such as hematopoietic progenitor cells cluster at ‘pre-metastatic niches’ creating an environment that is conducive for tumor cell adhesion and invasion.  At the pre-metastatic niche, newly recruited myeloid cells collaborate with other cells types residing in the tissue parenchyma. Together, these cells provide a platform of chemokines, growth factors, matrix-degrading enzymes and adhesion molecules, thereby accelerating assembly of the metastatic lesion. This model suggests that it may be beneficial for systemic therapies targeted to the metastatic microenvironment to be used early, perhaps even as an adjunct to the initial treatment of the primary tumor (Nature Reviews Cancer, 2009 9:285-293). Finally, there is the implication that treatments may need to be tailored to each stage of metastatic progression: pre-metastatic, micrometastatic and macrometastatic.

 His honors and awards include Distinguished Alumnus Brown University (2003), Princess Takamatsu Lectureship Award (2006), and the Leonard Weill Memorial Lecturer Award (2007). His work was highlighted in “Nature Milestones: Cancer”. In 2007, he was awarded a Presidential Medical Distinction Award by President Cavaco Silva of Portugal. Dr. Lyden is Co-Senior Editor for the first textbook dedicated to metastasis research and treatment, “Cancer Metastasis: Biologic Basis and Therapeutics” by Cambridge University Press, scheduled for publication for June 2010.

David Mankoff, MD, PhD

Professor of Radiology

University of Pennsylvania

Dr. David Mankoff is Professor of Radiology and Chief of the Division of Nuclear Medicine Clinical Molecular Imaging at the Perelman School of Medicine at the University of Pennsylvania. Dr. Mankoff is board-certified in Nuclear Medicine and holds a PhD in Bioengineering focusing on PET instrumentation. He practices Nuclear Medicine at the University of Pennsylvania, with a special interest in oncologic and endocrine applications of molecular imaging and treatment of endocrine tumors. Dr. Mankoff’s research focuses on molecular imaging of cancer, especially breast cancer, and emphasizes therapeutic monitoring and identifying factors mediating therapeutic resistance. Dr. Mankoff is the immediate past Chairman for the American Board of Nuclear Medicine, and he also Chairs the Experimental Imaging Sciences Committee of the American College of Radiology Imaging Network (ACRIN). Dr. Mankoff is on the editorial boards of Nuclear Medicine and Biology, Breast Cancer Research, Journal of Nuclear Medicine, and Clinical Cancer Research.

Sofia D. Merajver, MD, PhD

Professor of Internal Medicine and Epidemiology

University of Michigan

Dr. Merajver's program in cancer research comprises molecular and physical phenotypic studies of cell motility, and systems biology approaches in integration of cellular signaling and metabolism, with special focus on inflammatory and aggressive breast cancer phenotypes. We utilize a variety of in vitro, 2-D and 3-D model systems as well as targeted specific animal models of primary tumor growth and metastases. At a larger international scale, our work in global cancer health is highly multidisciplinary and aims to ameliorate health disparities in the US and globally, in close collaboration with partners in platforms in Ecuador and Latin America, North Africa and the Middle East, Sub-Saharan Africa, India, and China. She has supervised over 68 graduate and undergraduate students for two decades, and mentored 22 postdoctoral fellows and junior faculty who now participate as leaders in research. In total, she has mentored or co-mentored 108 scientists. Her collaborative work has spanned the disciplines of molecular genetics and clinical epidemiology in special populations in the US and globally, drug development, molecular and cell biology, mathematical modeling, and psychosocial determinants of outcomes in cancer. She is scientific director of the breast oncology program and I am a physician scientist with a translational focus of integrating molecular genetics of breast cancer with fundamental studies of the dynamics of breast cancer signal transduction and cell motility into innovative clinical strategies for breast cancer prevention and therapy. In the molecular biology of cancer and aggressive cancer phenotypes, our research has encompassed work on the role of rho and other signaling and cytoskeletal proteins in cancer, cell invasion, and motility, the role of copper in angiogenesis, and metabolism and signal transduction in cancer. Coupled to the experimental studies in live cells, her mathematical modeling group has been a fruitful collaboration with key colleagues over a decade, and has been concerned with the fundamental structure of information transmission in signal transduction cascades in cells. This work has brought together physicists, electrical engineers, and biological chemists working on different aspects of the problem both from a theoretical standpoint and for the experimental testing of the model's predictions. In the Merajver laboratory teams of molecular biologists are working alongside faculty and students in mathematics, bioinformatics, and engineering to model and understand the details of single cell motion and the key signaling intermediates that determine the switch between motion and proliferation, both structurally and metabolically. Taken together, this work is aimed at ascertaining the signaling dynamics that govern cellular motion and breast cancer metastases. She has served on the program committee of AACR and ASCO, and has been a reviewer in NIH and DOD study sections spanning multiple disciplines in cancer, for over 15 years. She is senior editor in Cancer Research and serves in several other journal editorial boards.

Richard A. Morgan, PhD

Staff Scientist

National Cancer Institute

Bio not available

Monica Morrow, MD, FACS

Chief of Breast Surgical Service

Memorial Sloan-Kettering Cancer Center

Monica Morrow is Chief of the Breast Service and Anne Burnett Windfohr Chair in Clinical Oncology at Memorial Sloan Kettering Cancer Center and Professor of Surgery at Weill Cornell Medical College. She is a graduate of Jefferson Medical College and did her surgical residency at the University of Vermont followed by a surgical oncology fellowship at Memorial Sloan Kettering Cancer Center. She was previously on the faculty at SUNY Health Science Center at Brooklyn, University of Chicago, and Northwestern University, and was Chair of Surgery at the Fox Chase Cancer Center. She was the 2012-13 President of the Society of Surgical Oncolo y and is an honorary Fellow of the Royal College of Surgeons of Ireland and the Royal College of Physicians and Surgeons of Glasgow. She is the recipient of the 2012 Gianni Bonnadonna Breast Cancer Award of the American Society of Clinical Oncolgy. She has given 46 named lectures and is the author of more than 400 publications.

Hyman B. Muss, MD

Professor of Medicine

Director of Geriatric Oncology

University of North Carolina at Chapel Hill

Dr. Muss is Professor of Medicine at the University of North Carolina School of Medicine, and the Director of the Geriatric Oncology Program at the UNC-Lineberger Comprehensive Cancer Center Program. With his colleague Dr. Ned Sharpless he is exploring the role of biomarkers of aging and their potential role as predictors of toxicity and survival in women with breast cancer. He also serves as the mentor for medical students, medicine residents, junior faculty, and most recently three Geriatric Oncology fellows.

He has a major interest and research expertise in the care of older women with breast cancer. He has developed and been PI of multiple clinical and translational trials and was the lead author of a CALGB trial and seminal NEJM article that compared standard with oral chemotherapy in older women with early stage breast cancer. He authored or co-authored over 300 manuscripts as well as numerous abstracts and book chapters.

In addition, he currently co-chairs the Alliance (previously Cancer and leukemia Group B) CALGB Committee on Cancer in the Elderly and was previously co-chair of the Breast Committee. Dr. Muss has been Chair of the Medical Oncology Section of the American Board of Internal Medicine and also served as a member of the Board of Directors. In addition he is a past elected member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and the ASCO's Conquer Cancer Foundation. He has been awarded the B.J. Kennedy Award in Geriatric Oncology by ASCO, the Umberto Veronesi Educator award by the 6th Inter-American Breast Cancer Conference, and more recently the 2012 Brinker Award for Scientific Distinction in Clinical Research. He has also served in the U.S. Army in Vietnam where he was awarded the Bronze Star medal.

Lisa A. Newman, MD, MPH, FACS

Director, Breast Care Center

Professor of Surgery

University of Michigan Comprehensive Cancer Center

Dr. Newman is Professor of Surgery and Director of the Breast Care Center for the University of Michigan in Ann Arbor, Michigan, where she also serves as Program Director for the Breast Fellowship. Dr. Newman obtained her undergraduate education and Masters Degree in Public Health from Harvard University. She attended medical school and completed her general surgery residency training at the State University of New York Health Science Center at Brooklyn.  She completed her fellowship in surgical oncology at the M.D. Anderson Cancer Center in Houston, Texas.

Her extensive research related to disparities in breast cancer risk and outcome has been published in numerous peer-reviewed medical journals and was recently featured on CNN's documentary "Black in America 2". She has held leadership positions with the Society of Surgical Oncology (Executive Council; Disparities Committee Chair), the American Society of Clinical Oncology (Chair, Health Services Committee; Chair, Disparities Advisory Board) and served as editorial section editor for the journals Cancer (Disparities Section Editor) and Annals of Surgical Oncology (Breast Section Editor). She also serves on the editorial boards for CA- A Cancer Journal for Clinicians; Journal of Clinical Oncology; and Breast Cancer Research and Treatment. She also serves on the Breast Prevention Section of the National Comprehensive Cancer Network. She maintains a very active community service record, and currently serves as Chief National Medical Advisor for the Sisters Network, Inc., a national African American breast cancer survivors support organization. Her current disparities-related research program involves a partnership between the University of Michigan and the Komfo Anoyke Teaching Hospital in Kumasi, Ghana.

Polly Niravath, MD

Assistant Professor

Baylor College of Medicine

Dr. Niravath is an assistant professor in Baylor College of Medicine's Lester and Sue Smith Breast Center. She completed her internal medicine residency and hematology/oncology fellowship at Baylor College of Medicine. She is a board certified in Internal Medicine, Oncology, and Hematology.

As a specialized breast oncologist, she specializes in issues pertaining to breast cancer survivorship. I direct the Breast Cancer Survivorship Clinic at the publicly funded county clinic, Smith Clinic. This is one of the first specialized survivorship clinics to be offered in a public hospital in the nation. She provides all patients in the clinic with a treatment summary and survivorship care plan to help them better understand their treatment and the potential long term side effects associated with treatment. She also attends to the long term problems which many survivors have, including lymphedema, post-mastectomy pain syndrome, peripheral neuropathy, depression, and premature menopause.

Her clinical research focuses on aromatase inhibitor-induced arthralgia and vaginal dryness/sexual dysfunction. She has written a review article on aromatase inhibitor-induced arthralgia (AIA), which is one of the first articles to comprehensively address the issue and offer a practical, evidence-based approach to the management of AIA. She has also published an article on special issues in the care of young breast cancer survivors, including matters such as fertility, atrophic vaginitis, and sexual dysfunction. Additionally, she serves on several panels, including a joint panel with Texas Children's Hospital; they are making a national, evidence-based guideline for the care of breast cancer survivors. She also serves as a consultant for the Epic electronic medical record to construct a survivorship care plan for cancer survivors with Epic.

Her clinical experience and her research focuses mainly on symptom control, and this is her primary interest. Quality of life is extremely important for all cancer patients, and this must be carefully balanced against other goals of care, especially in the setting of metastatic disease. She recently spoke at a regional conference for the Sisters Network (national group for African American women with breast cancer) on the topic of advanced breast cancer, regarding what the goals of care should be for patients with metastatic breast cancer, and how to offer effective treatment with minimal sacrifice of quality of life.

Andre Nussenzweig, PhD

Branch Chief, Laboratory of Genome Integrity

National Institutes of Health

Dr. Nussenzweig received his Ph.D. in Physics from Yale University in 1989. He completed his postdoctoral training in atomic physics in Paris with Dr. Serge Haroche, who was awarded the Nobel prize in Physics in 2012. Subsequently, Dr. Nussenzweig became a Research Fellow at Memorial Sloan-Kettering Cancer Center prior to joining the Experimental Immunology Branch as a tenure track investigator in 1998. Dr. Nussenzweig received tenure at NIH in 2003. In 2011, Dr. Nussenzweig established a new department at NCI called the Laboratory of Genome Integrity, which will provide a focal point for the rapidly exploding area of research on mechanisms that maintain genome stability.

C. Kent Osborne, MD

Professor of Medicine & Molecular & Cell Biology

Baylor College of Medicine

Dr. C. Kent Osborne was born in 1946 in St. Louis, Missouri. He received his AB and MD degrees from the University of Missouri, both with honors. He completed his residency at Johns Hopkins in 1974, and his medical oncology fellowship at the NCI in 1977. He was a faculty member at The University of Texas Health Science Center at San Antonio, where he rose to Professor and Director of the Division of Medical Oncology. In 1999 Dr. Osborne moved to Baylor College of Medicine to develop a Breast Center and in 2005 he became Director of the new cancer center.

Dr. Osborne is a physician scientist.  His research has focused on understanding the mechanisms of resistance to therapies targeting ER and HER2 and the cross-talk between these pathways.  For 10 years Dr. Osborne was Chairman of the Breast Committee of the Southwest Oncology Group, where he oversaw numerous nationwide clinical trials investigating new treatment strategies.  He has been the Principal Investigator of the Baylor Breast Cancer SPORE grant for 20 years.  Among his previous awards are the Komen Foundation Award for Scientific Distinction and the Brinker International   Award.

Charles M. Perou, PhD

Professor of Genetics and Pathology & Laboratory Medicine

University of North Carolina at Chapel Hill

Dr. Perou’s research crosses the disciplines of genomics, cancer research, bioinformatics, epidemiology, and clinical trials. His major contribution to the field has been in the characterization of the diversity of breast tumors, which resulted in the discovery of the Basal-like/Triple-Negative Breast Cancer Subtype. This genomic-based classification, known as the intrinsic subtypes of breast cancer, is now being used to help physicians better understand why some cancers do or do not respond to standard therapies, and to tailor treatment to each patient’s disease subtype.

He and his colleagues demonstrated that breast tumors can be classified into five molecular subtypes, with his lab focusing particular attention on the Basal-like subtype. He is also elucidating the genetic causes that give rise to each subtype, modeling these events in genetically engineered mouse models, and then using these animal models to investigate the efficacy of new drugs and new drug combinations. Dr. Perou has also translated these molecular finding to a much wider patient population. Using a North Carolina-based epidemiological population-based study (Carolina Breast Cancer Study), he and his colleagues found that pre-menopausal African American women are diagnosed with Basal-like tumors approximately twice as often as their Caucasian counterparts, thus providing insight into racial outcomes disparities differences.

Dr. Perou has authored more than 180 peer reviewed articles, and is an inventor on 2 US patents. He is the Faculty Director of the LCCC Bioinformatics Core Resource, and Co-Director of the LCCC Breast Cancer Research Program. He is a member of the ALLIANCE/CALGB Breast Committee, and of the Translational Breast Cancer Research Consortium. He earned his BA in Biology from Bates College, his PhD in Cell Biology from the University of Utah, and performed his postdoctoral work in the laboratory of David Botstein (then at Stanford University). He has been a faculty member at UNC-CH since 2000. Lastly, he was the recipient of the 2009 AACR Outstanding Investigator Award for Breast Cancer Research, the 2011 Danaher Scientific and Medical Award that is a Susan G. Komen Foundation Award for Scientific Distinction, and the 2012 European Institute of Oncology Breast Cancer Therapy Award.

David Piwnica-Worms, MD, PhD

Professor of Radiology

Washington University

Dr. Piwinica-Worms leads an innovative program at the Molecular Imaging Center that is dedicated to devising new non-invasive ways to analyze and monitor many different biological processes in living tissue. The imaging and scanning technologies that Dr. Piwnica-Worms and his colleagues employ include PET scans, MRI imaging and bioluminescence. Their overall goal is to advance the understanding of biology and medicine through noninvasive in vivo investigation of gene expression and molecular interactions in the context of the whole organism. Dr. Piwnica-Worms is co-director of the BRIGHT (Bridging Research with Imaging, Genomics and High Throughput) Institute.

Peggy Porter, MD

Head, Breast Cancer Research Program

University of Washington

Dr. Peggy Porter of the Human Biology Division of the FHCRC and the Department of Pathology UW leads an effort to launch a new Shared Resource within the Cancer Consortium that will make biological specimens more readily available for research, improving disease detection and the treatment of solid tumor cancers.  The Consortium Biospecimen Resource (CBR), funded in its initial three years by nearly $5 million from the Life Sciences Discovery Fund, will both virtually unite existing specimen repositories within the Fred Hutchinson/University of Washington Cancer Consortium and provide a centralized specimen collection service for researchers. Pathologists Larry True, Kim Allison and Rodney Schmidt lead the effort in Anatomic Pathology and have joined with Porter and the informatics group in the UW Institute of Translational Health Sciences (ITHS) to implement an automated system of research specimen collection and distribution. The presentation will highlight progress made in the first year of funding and plans for the future.

Peter M. Ravdin, MD, PhD

Director of the Breast Cancer Program

UT Health Science Center San Antonio

Dr. Ravdin has broad experience in the preclinical and clinical sciences. Within the clinical realm he has worked broadly in laboratory based estimates of prognosis and prediction of treatment efficacy. His special focus has been breast cancer and other malignancies: as a clinician actively caring for patients in the clinic; and as a researcher with an interest (and a publication record) in breast cancer drug development, breast cancer epidemiology, and the basic biology of breast cancer. Particularly because of his interest in breast cancer epidemiology, he has developed an interest in breast and other cancers risk reduction.

Andrea Richardson, MD, PhD

Associate Professor of Pathology

Dana-Farber Cancer Institute

Dr. Andrea L. Richardson is an Associate Professor of Pathology at Brigham and Women's Hospital, Harvard Medical School in Boston.  Her area of excellence is breast cancer genetics and pathobiology.  She spend most of her professional effort engaged in translational research, frequently with multi-disciplinary teams in which she both leads and participates in research projects.  She established and direct the breast tissue repository at Brigham and Women's Hospital and Dana Farber Cancer Institute and has extensive experience in tissue-based molecular assays including gene expression analysis, genomic analysis by SNP array profiling, immunohistochemistry, fluorescence in situ hybridization, and mutation detection by sequence analysis. Her laboratory research has focused on characterizing the molecular aberrations in subtypes of breast cancer important for pathogenesis, tumor progression, and tumor response to therapy.  This work includes identifying the relationship between sporadic and BRCA 1-associated basal-like breast cancer in X-chromosome abnormalities, high level of chromosome rearrangement, and response to DNA damaging drugs.

Mothaffar Rimawi, MD

Medical Director, Associate Professor

Baylor College of Medicine

As a board certified oncologist and a breast cancer researcher, his expertise are relevant to his duties as a program committee member.

He trained in internal medicine, hematology/oncology, and breast oncology at Baylor College of Medicine.  Also performed published peer reviewed basic and clinical research.

He is an associate professor and is involved in patient care, education, in addition to research.

Alistair Ring, MRCP, MD

Consultant in Medical Oncology

Brighton and Sussex Medical School

Dr. Ring is a senior lecturer and honorary consultant in medical oncology at Brighton and Sussex Medical School. His oncology training was based at the Royal Marsden, St George's and Guy's Hospitals, London. Since February 2008 Dr Ring has been developing a research programme for cancer care in the elderly at Brighton and Sussex Medical School. To date this programme has recruited over 1200 patients to research studies addressing fitness for treatment, biological markers of ageing , nutrition, communication, epidemiology and treatment preferences in older people with cancer . He is a member of the National Cancer Research Institute Breast Clinical Studies Group, and sits on the European Organisation for the Research and Treatment of Cancer (EORTC) Task Force for Cancer in the Elderly. He is also a member of the International Society of Geriatric Oncology and the American Society of Clinical Oncology.

Jeffrey M. Rosen, PhD

Professor

Baylor College of Medicine

Dr. Jeffrey Rosen received his BA in Chemistry from Williams College and his Ph.D. in Biochemistry from SUNY at Buffalo at the Roswell Park Cancer Institute. He did his postdoctoral research with Dr. Bert W. O'Malley at Vanderbilt University School of Medicine, and was a Visiting Professor at the Imperial Cancer Research Fund Laboratories in London, and at the Swiss Institute of Cancer Research, EPFL in Lausanne, Switzerland. Dr. Rosen is currently a Distinguished Service Professor and the C.C. Bell Professor of Molecular & Cellular Biology and Medicine at Baylor College of Medicine. He has been the recipient of two prestigious MERIT awards from the National Institutes of Health and is the principal investigator on a grant entitled, "Hormonal Regulation of Breast Cancer" currently in its thirty-seventh year of consecutive funding. His laboratory has authored 247 publications and book chapters dealing with hormonal regulation of gene expression, signal transduction, normal mammary gland development, breast cancer, transgenic animal models of breast and prostate cancer, mammary gland stem and progenitor cells, and noncoding RNAs. Dr. Rosen has been the recipient of the Endocrine Society Edwin B. Astwood Award, the Michael E. DeBakey, Excellence in Research Award and the Susan G. Komen Brinker Award for Scientific Distinction. He is currently a member of the Susan G. Komen and the Breakthrough Breast Cancer Scientific Advisory Committees, and serves on the editorial boards of several journals, including Breast Cancer Research and Cancer Discovery. He was a co-organizer of the AACR Special Conference on Advances in Breast Cancer Research held in October of 2011.

Stuart J. Schnitt, MD

Director, Division of Anatomic Pathology

Harvard Medical Faculty Physicians at

Beth Israel Deaconess Medical Center

Dr. Schnitt has been a faculty member, invited speaker, and keynote lecturer in numerous pathology, medical oncology, radiation oncology, surgery/surgical oncology, radiology, and multidisciplinary courses related to breast diseases and breast cancer throughout the US and around the world. He has been the course director for numerous post-graduate courses in surgical pathology and breast pathology in the US and abroad. In particular, he has been the director of an annual Harvard Medical School Department of Continuing Education course in breast pathology since 2002. This course was the first post-graduate pathology course offered by a US Medical School that was exclusively devoted to breast pathology. Dr. Schitt has chaired or moderated numerous scientific sessions at national and international pathology and breast cancer meetings. He was one of two people responsible for organizing the breast pathology program for the bi-annual meeting of the International Academy of Pathology that was held in Montreal in 2006. He has spent 4 years on the Education Committee of the United States and Canadian Academy of Pathology (USCAP), the leading professional pathology society for providing post-graduate education in anatomic and molecular pathology and is a past president of the USCAP (2010-2011).

Geoffrey I. Shapiro, MD, PhD

Director, Early Drug Development Center

Dana-Farber Cancer Institute

Dr. Shapiro received his PhD in 1987 and his MD in 1988 from Cornell University, followed by postgraduate training in internal medicine at Beth Israel Hospital, Boston, where he  served as chief medical resident.

He completed a fellowship in medical oncology at Dana-Farber Cancer Institute, during which he investigated the role of cell-cycle-related proteins in lung cancer. He joined the Dana-Farber faculty in 1994.

Joseph A. Sparano, MD

Associate Chair Department of Oncology

Professor of Medicine & Women's Health

Montefiore Medical Center-Weiler Division

Dr. Joseph Sparano is Professor of Medicine & Women's Health at the Albert Einstein College of Medicine, Associate Chairman for Clinical Research in the Department of Oncology at Montefiore Medical Center, and Associate Director for Clinical Research at the Albert Einstein Cancer Center. He also serves as Vice Chair of the Eastern Cooperative Oncology Group (ECOG), Vice-Chairman of the AIDS Malignancy Consortium, and Chair of the ECOG Breast Cancer Committee. His research has focused on developmental therapeutic approaches for breast cancer, lymphoma, and HIV-associated cancers, and therapeutic applications of genomic profiling in cancer.

Michael Stratton, FMedSci FRS

Director

The Wellcome Trust Sanger Institute

Mike Stratton studied medicine at Oxford University and Guy’s Hospital, specialised in histopathology and obtained his PhD at the Institute of Cancer Research, London. His research is in cancer genetics. Early studies focused on inherited predisposition, notably discovery of the breast cancer susceptibility gene BRCA2. Subsequently, he initiated genome-wide sequencing for somatic mutations in cancer, discovering BRAF mutations in malignant melanoma and describing basic mutational patterns in cancer genomes. He is Director of the Wellcome Trust Sanger Institute, Hinxton, UK.

Matthew Vander Heiden, MD, PhD

Assistant Professor of Biology

Massachusetts Institute of Technology

Dr. Vander Heiden is the Howard S. (1953) and Linda B. Stern Career Development assistant professor of biology at MIT and an instructor in medicine at both Harvard Medical School and the Dana-Farber Cancer Institute. He has been a Member of the Scientific Advisory Board at Agios Pharmaceuticals, Inc. since 2008. He received the Burroughs Wellcome Fund Career Award for Medical Scientists in 2009.  Dr. Vander Heiden earned his B.S. in Biological Chemistry, M.D. and Ph.D. from the University of Chicago.

Laura J. van 't Veer, PhD

Professor and Direction

University of California San Francisco

Dr. van ‘t Veer is a world renowned Molecular Biologist, former Head of Diagnostic Oncology at the Netherlands Cancer Institute, and inventor of MammaPrint. She is the P.I. of both the Athena Breast Health Network at UCSF and the Bay Area Breast SPORE and Leader of the Breast Oncology Program in the Helen Diller Family Comprehensive Cancer Center. Dr. van ‘t Veer’s research focuses on Personalized Medicine, to advance that patient management is based on knowledge of the genetic make-up of the tumor as well as the genetic make-up of the patient. This allows to optimally assign systemic therapy for those patients that are in need of such treatment and to ensure the selection of the therapy that is most effective. Dr. van ‘t Veer’s research shows that molecular diagnostics and microarray genomics technology increasingly impacts patient management. Molecular Genomics contributes to the knowledge of who is at risk for breast cancer, how external factors may influence this risk, whether breast tumors are likely to metastasize or not, and which subtype of tumors will likely respond to what therapy.

H. Gilbert Welch, MD, MPH

Professor of Medicine

Darthmouth Institute for Health Policy & Clinical Practice

Dr. Welch is a general internist at the White River Junction VA and a professor of Medicine at the Dartmouth Institute for Health Policy and Clinical Research in the Geisel School of Medicine. He is also a professor of Public Policy at Dartmouth College and a professor of Business Administration at the Amos Tuck School.

For the 25 years he has been practicing medicine, Dr. Welch has been asking hard questions about his profession. He has published on a variety of topics: health policy for bone marrow and organ transplantation, health care for the uninsured, geographic variation, physician profiling and diagnostic testing. His arguments are frequently counter-intuitive, even heretical, yet have regularly appeared in the country's most prestigious medical journals — Annals of Internal Medicine, Journal of the American Medical Association, the New England Journal of Medicine and the Journal of the National Cancer Institute — as well as in op-eds in the Los Angeles Times and the New York Times.

Dr. Welch is very much part of the “Dartmouth School” that questions the assumption that more medical care is always better. His research has focused on the assumption as it relates to diagnosis: that the best strategy to keep people healthy is early diagnosis – and the earlier the better. He has delineated the side-effects of this strategy: physicians test too often, treat too aggressively and tell too many people that they are sick. Much of his work has focused on overdiagnosis in cancer screening: in particular, screening for melanoma, thyroid, lung, breast and prostate cancer. His first book, SHOULD I BE TESTED FOR CANCER? Maybe not and here's why (UC Press 2004) was written while he was a Visiting Scientist at the International Agency for Research on Cancer and was one of the six "best books" listed by Malcolm Gladwell in The Week. He has recently published a second book, OVERDIAGNOSED: Making people sick in the pursuit of health (Beacon Press 2011).

Max S. Wicha, MD

Director

University of Michigan Comprehensive Cancer Center

Dr. Max Wicha received his medical degree from Stanford University and trained in internal medicine at the University of Chicago. He then went on to the National Cancer Institute, where he trained in clinical oncology and cancer biology. Dr. Wicha joined the faculty of the University of Michigan in 1980 and served as chief in the Division of Hematology/Oncology in the Department of Internal Medicine, from 1984 to 1993. He has been the director of the U-M Comprehensive Cancer Center since its inception in 1986. Dr. Wicha is an active clinician, specializing in the treatment of breast cancer patients, and is nationally known for his research in the field of breast oncology, particularly the study of how breast cancer cells grow and metastasize.

Eric P. Winer, MD

Chief, Division of Women's Cancers

Dana-Farber Cancer Institute

Dr. Winer received his MD from Yale University in 1983, and later completed training in internal medicine and served as chief resident at Yale-New Haven Hospital. He subsequently was a fellow in hematology-oncology at Duke University Medical Center, and from 1989 to 1997 served on the Duke faculty, where he became codirector of the multidisciplinary breast program. In 1997, he joined Brigham and Women's Hospital and DFCI, where he is director of the Breast Oncology Center.

Wendy A. Woodward, MD, PhD

Associate Professor, Radiation Oncology

UT MD Anderson Cancer Center

Dr. Woodward is an Associate Professor and the Director of Clinical Breast Radiation Research in Department of Radiation Oncology at The University of Texas M.D. Anderson Cancer Center (MDACC). She is a physician-scientist specializing in clinical breast radiation oncology with a lab focused on breast cancer stem cell biology and radiobiology.  She is deputy director of the MDACC Inflammatory Breast Cancer clinic and Research Program and is dedicated to advancing the radiation treatment and biologic understanding of inflammatory breast cancer through laboratory, translational, and clinical research.  Nationally, she serves as the liaison between the breast working group and the translational research program in the Radiation Therapy Oncology Group devoted to designing translational endpoints for multi-institutional trials in breast radiation therapy. Specific interests include studying molecular determinants of treatment resistance in breast cancer stem cells and novel treatment of inflammatory breast cancer. Finally, Dr. Woodward has a strong interest in education and mentoring trainees in both clinical and translational breast cancer research and was a finalist in the Chamberlain Outstanding Mentorship Award at MDACC in 2011.

Jeff Wrana, PhD

Senior Investigator

Mount Sinai Hospital

Dr. Jeffrey Wrana is a Senior Investigator at the Samuel Lunenfeld Research Institute, Mount Sinai Hospital and a Professor in the Department of Medical Genetics and Microbiology at the University of Toronto. Using high-throughput proteomics and genetic tools, Dr. Wrana's research program seeks to understand morphogen signaling pathways, the higher organizational structure, or network into which they are integrated and how these systems control cell behaviour in development and cancer.

Dr. Wrana received his PhD in biochemistry in 1991 from the University of Toronto, and completed postdoctoral training at the Memorial Sloan-Kettering Cancer Center in New York. He is a Howard Hughes Medical Institute International Research Scholar (2002-6) and has been awarded a number of priizes for his research excellence, including the William E. Rawls Prize from the National Cancer Institute of Canada (1998), the Merck Frosst Prize from the Canadian Society of Biochemistry Molecular and Cell Biology (2002) and the Paul Marks Prize from Memorial Sloan Kettering Institute (2005).

Douglas Yee, MD

Director & Professor of Medicine & Pharmacology

University of Minnesota

Douglas Yee, M.D. ls director of the Masonic Cancer Center, University of Minnesota. A professor in the Departments of Medicine and Pharmacology, Dr. Yee holds the John H. Kersey Chair In Cancer Research. He is internationally known for his breast cancer research and more specifically for his laboratory research focused on the growth regulation of tumors by the insulin-like growth factors. He has published over 170 articles in journals and books. He also maintains an active clinical practice In breast medical oncology at the Breast Center, University of Minnesota Medical Center, Fairview.

Dr. Yee has served on numerous national grant review panels and cancer research and treatment policy panels Inducting the National Cancer  lnstitute's Cancer center  Parent Committee and the National Institutes of Health and Department of Defense Integration Panel.  Dr. Yee Is a Pew Scholar and a Komen Scholar for the Susan G Komen for the Cure.  He is also a member of the Scientific Advisory Committee for the Love/Avon Army of Women. Dr. Yee is the chair of the Scientific  Program Committee for the American Society of Clinical oncology's 2013 Annual Meeting.  Of note, in addition to the CTRC-AACR

San Antonio Breast Cancer Symposium Program Planning Committee, Dr. Yee serves on numerous external advisory boards Including the National Surgical Adjuvant Breast and Bowel Project and several cancer centers (University of Michigan, Baylor College of Medicine, University Of Cincinnati, and Vanderbilt University) as well as other such bo<irds across the country.

Dr. Yee graduated from tile University of Michigan in Ann Arbor, earned his medical degree from the University of Chicago, and completed his residency in internal medicine at the University of North Carolina In Chapel Hill and his fellowship in medical oncology at the National Cancer Institute In Bethesda, MD. Before coming to \he University of Minnesota, he held facylty positions at Georgetown University Medical Center In Washington, D.C., and at the University ofTexas Health Science Center In San Antonio.

Xiang Zhang, PhD

Assistant Professor

Baylor College of Medicine

Dr. Zhang got his Ph.D. degree in 2006 at Columbia University. His thesis work focused on the genomics of pre-mRNA splicing, a process over 90% of vertebrate genes undergo during their expression. I then joined  Dr. Joan Massague's lab and started my research on cancer metastasis. In 2011, he was recruited to the Breast Center of Baylor College of Medicine as a McNair Scholar and a tenure­ track assistant professor. My lab is currently continuing metastasis studies in breast cancer. Their especially interested in the prediction (prognosis), detection , and elimination of microscopic metastases of breast tumors.

Dr. Zhang was the first author of 12 papers or manuscripts  that were and will  be published  in journals including Nature,  Cancer  Cell,  Genes and  Development , PNAS,  Genome  Research and MCB.  He also co-authored  another  10 papers published  in Cell, Nature, Cancer  Cell, Nature Medicine  and etc. He was the invited speakers of a number  of international  conferences  includ ing the Gordon Conference on Mammary  Gland Biology (20 10) and Advanced  Breast  Cancer  First  Consensus (201 1). His  awards includ e "Thesis  with  Distinction" by Columbia University  (2006), the McNair  Scholarship by  Baylor  College of  Medicine (20 I 1) and  Pathway  to  Independence  Award  by  NCI  (20 I 0-2014). He is  ad hoc reviewer of Science, Cancer Research, RNA, Nucleic Acid  Research,  BM C Bioinformali cs and Breast Cancer Research, and  is a active member of American  Association  of Cancer  Research  (AACR).